misleading statements

Picard Medical faces securities fraud class action over misleading statements and stock promotion in 2025. Investors must file claims by April 3, 2026.

Levi & Korsinsky launches class action against Paysafe for securities fraud. Shareholders must file lead plaintiff requests by April 7, 2026.

BellRing Brands faces securities lawsuit alleging false sales disclosures. Stock fell 51.6% after company allegedly misattributed inventory hoarding to market demand.

BellRing Brands faces securities fraud lawsuit alleging it misrepresented sales growth, claiming inventory stockpiling rather than organic demand drove performance, inflating stock valuations.

Class action lawsuit filed against Inovio Pharmaceuticals for allegedly making false statements about device manufacturing capabilities and regulatory timelines between October 2023 and December 2025.

uniQure faces class action lawsuit alleging misleading FDA approval statements and understated BLA timeline risks. Investors who purchased securities between September-October 2025 may be eligible to participate.

REGENXBIO faces securities class action alleging false statements about RGX-111 gene therapy program and clinical trial outcomes. Investors from February 2022-January 2026 may recover damages.

Portnoy Law Firm filed securities class action against Ultragenyx Pharmaceutical, alleging the company made false statements about investigational drug setrusumab and concealed material clinical trial risks.

Varonis Systems faces class action lawsuit after stock plunged 48.67% on October 29 following missed revenue projections and weak customer conversions disclosure.

BellRing Brands faces securities lawsuit alleging false statements about financial performance and growth. Class action covers November 2024 through August 2025 for affected investors.

Ramaco Resources faces securities litigation over alleged misrepresentations regarding Brook Mine operations. Investors who purchased stock during July-October 2025 should consult legal counsel about joining the class action.

Ultragenyx faces securities lawsuit alleging false claims about drug setrusumab for bone disease. Investors have until April 6, 2026 deadline to join class action.

Ultragenyx faces class action lawsuit for allegedly misleading investors about setrusumab efficacy and failing to disclose Phase III trial risks adequately.

Class action lawsuits filed against Ultragenyx and Mereo after Phase III clinical trials for setrusumab failed. Stock prices plummeted 42% and 88% respectively following the announcement.

Oracle faces securities lawsuit for allegedly misrepresenting AI infrastructure investment returns and failing to disclose significant financial obligations and project delays.

REGENXBIO faces class action lawsuit alleging false statements about RGX-111 gene therapy trial results, covering securities purchased between February 2022 and January 2026.

Mereo BioPharma faces class action lawsuit over allegedly misleading disclosures about failed Phase 3 clinical trials. Investors who purchased shares between June 2023 and December 2025 may be eligible.

Mereo BioPharma faces securities lawsuit for allegedly making false statements about setrusumab trial results, causing artificially inflated stock prices and investor losses.

PomDoctor Ltd. faces securities lawsuit alleging false statements, social media manipulation, and insider selling. Investors who bought stock October-December 2025 must act before April 7, 2026 deadline.

BellRing Brands faces securities fraud investigation for allegedly misrepresenting 2025 sales growth, attributing gains to retail inventory buildup rather than organic demand. Stock fell 33%.